

SCIENTIFIC PROGRAM

- 08:30** **Welcome**
David Kerr
ESMO President
Manuel Llombart
General Manager, Fundación Instituto Valenciano de Oncología, Valencia, Spain
- 08:45-09:25** **Keynote Lecture: Molecular Biology In Ovarian Cancer**
Robert C. Bast Jr
The University of Texas, MD Anderson Cancer Center, Houston (Texas), USA

SESSION-1 EARLY DETECTION

- CHAIRS:** Elise C. Kohn
National Cancer Institute, Bethesda (Maryland), USA
Andrés Cervantes
Clinic University Hospital, Valencia, Spain
- 09:25-09:45** **Defining the Target for Early Detection**
Patrick O. Brown
Stanford University School of Medicine, Stanford (California), USA
- 09:45-10:05** **Designing Early Detection Programs for Ovarian Cancer**
Nicole Urban
Fred Hutchinson Cancer Research Center, Seattle (Washington), USA
- 10:05-10:20** **Discussion**

SESSION-2 PRIMARY OVARIAN CANCER -PART-1

- CHAIRS:** Jonathan Berek
Stanford University School of Medicine, Stanford (California), USA
Sergi Martínez
Clinic Hospital, Barcelona, Spain
- 10:20-10:40** **Quality Control in Ovarian Cancer Surgery**
Neville F. Hacker
Royal Hospital for Women, Randwick, Australia
- 10:40-11:00** **Is the use of PET/CT Leading to Stage Migration?**
Svend A. Engelholm
Copenhagen University Hospital, Copenhagen, Denmark
- 11:00-11:20** **Preoperative Serum CA125 Levels and Risk of Suboptimal Cytoreduction in Ovarian Cancer**
Sang-Yoon Park
Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Ilsan-gu Madu-dong, Goyang, Republic of Korea
- 11:20-11:30** **Discussion**
- 11:30-12:00** **Coffee break**

SESSION-3 PRIMARY OVARIAN CANCER -PART2

- CHAIRS:** Nicoletta Colombo
European Institute of Oncology, Milan, Italy
Jan B. Vermorken
University Hospital Antwerp, Edegem, Belgium
- 12:00-12:45** **Dose Dense Therapy is of Benefit in Primary Treatment of Ovarian Cancer?**
PRO: Noriyuki Katsumata
National Cancer Center Hospital, Tokyo, Japan
CON: Maria EL Van der Burg
University Hospital Dijkzigt, Rotterdam, The Netherlands
Discussion
- 12:45-13:30** **Follow up with CA125 After Primary Therapy of Advanced Ovarian Cancer has Major Implications for Treatment Outcome and Trial Performances**
PRO: Andreas DuBois
Dr.-Horst-Schmidt-Kliniken, Wiesbaden, Germany
CON: Gordon Rustin
Mount Vernon Cancer Center, Northwood (Middlesex), United Kingdom
Discussion
- 13:30-14:55** **Lunch**

SESSION-4 RANDOMIZED TRIALS IN OVARIAN CANCER

- CHAIRS:** Bradley J. Monk
Comprehensive Cancer Center, Creighton University School of Medicine at St. Joseph's Hospital and Medical Center Phoenix (Arizona), USA
Sandro Pignata
National Cancer Institute Fondazione Pascale, Naples, Italy
- 15:00-15:20** **Optimal Assessment of Response in Ovarian Cancer (Recist 1.1 Criteria, CA125...)**
Elizabeth Eisenhauer
NCIC Clinical Trials Group, Kingston (Ontario), Canada
- 15:20-15:45** **Update of Randomized Trials in First Line**
Michael Bookman
Arizona Cancer Center, Tucson (Arizona), USA
- 15:45-16:10** **Update of Randomized Trials in Recurrent Disease**
Eric Pujade-Lauraine
Hôpital Hôtel-Dieu, Paris, France
- 16:10-16:30** **Report of the 4th OCCC**
Gavin Stuart and Henry Kitchener (on behalf of GCIG)
- 16:30-17:00** **Discussion**
- 17:00-17:30** **Coffee break**

SESSION-5 NEW THERAPIES IN OVARIAN CANCER

- CHAIRS:** Stanley B. Kaye
The Royal Marsden Hospital, London, United Kingdom
Antonio González-Martín
Centro Oncológico MD Anderson International España, Madrid, Spain
- 17:30-18:10** **Antiangiogenic Therapy**
PRO: Robert A. Burger
Fox Chase Cancer Center, Philadelphia (Pennsylvania), USA
CON: Maurie Markman
Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia (Pennsylvania), USA
Discussion
- 18:10-18:25** **Parp Inhibition**
Cristiana Sessa
Ospedale San Giovanni, Bellinzona, Switzerland
- 18:25-18:45** **Other New Therapies**
David R. Spriggs
Memorial Sloan-Kettering Cancer Center, New York (New York), USA
- 18:45-19:00** **Discussion**
- 19:00-19:15** **Remarks and Conclusions**
Andrés Poveda
Fundación Instituto Valenciano de Oncología, Valencia, Spain



Advanced Ovarian Cancer:
Optimal Therapy. Update

Valencia, Spain, 4th March 2011

venue

Palau de la Música
Rodrigo Meeting Room
Paseo de la Alameda, 30
46030 Valencia (Spain)

language

The official language of the Symposium is English. Simultaneous translation into Spanish will be provided

credits

Accredited by the European Society for Medical Oncology Educational Committee for its medical oncology certification approval program with **8 ESMO MORA category 1 points.**

SYMPOSIUM SECRETARIAT

Doctaforum, Congresos y Reuniones Científicas
Av. Campo de Calatrava, 17, 4-PB-1
28034 Madrid, Spain
Tel.: +34 91 372 0203
Fax: +34 91 735 0454
E-mail: aocsymp2011@doctaforum.com

organized by



under the AUSPICES OF



Organized by:



doctaforum.com/aocsymp

DIRECTORS

Andrés Poveda
Fundación Instituto Valenciano de Oncología, Valencia, Spain

Jan B. Vermorken
University Hospital Antwerp, Edegem, Belgium



scientific committee

Andrés Cervantes (ESMO, GEICO)
Antonio González (ESMO, GEICO)
Jan B. Vermorken (ESMO)
Andrés Poveda (ESMO, GEICO)

Please fill in all details in capital letters

REGISTRATION AND ACCOMMODATION FORM

PERSONAL DATA

Family name _____ First name _____

Department _____

Institution/Hospital _____

Hospital address _____

Postal code _____ City _____ Country _____

Telephone _____ Fax _____ E-mail _____

Personal address _____

All personal data requested in this form is required in order to process your registration. Personal data will be kept by Doctaforum (address: Av. Campo de Calatrava 17, 4PB-1, 28034 Madrid, Spain) in order to manage your registration. You have the right to access, rectify, cancel and oppose this data by sending your written request to Doctaforum.

REGISTRATION FEE

Non ESMO members 590,00 €

ESMO members (25% discount applies) 442,50 €

The registration fee for symposium attendees covers: Participation in all conference sessions, educational material, lunch, coffee breaks and taxes.

Registration does not guarantee hotel space. If you would like help in reserving accommodation, please complete the section below.

HOTEL ACCOMMODATION

Hotel Silken Puerta Valencia (4*)

Cardenal Benlloch, 28
46021 Valencia

Single Room

109,74€

Double Room

123,90€

Arrival date _____ Departure date _____ Room type _____

_____ room(s)x _____ Euros/night= _____ Euros total.

Above rates include taxes and breakfast.

INFORMATION

Pre-payment of the total amount is required in order guarantee hotel reservation and registration. Method of Payment:

- Banker's draft, made payable to "Doctaforum"
- Bank transfer to "Doctaforum" at the following account:
Account No: 0081-7116-65-0001094519
Swift Code: BSABESBBXXX
IBAN: ES3700817116650001094519

- All payments must be made in EURO
- All payments must be free of charges to the receiver.
- Hotel reservation will be effective and confirmed when complete payment has been received by the Symposium Secretariat Doctaforum.

Due to **space restrictions**, attendance will be limited to a maximum number of 400 attendees. Registrations will be closed as soon as the first 400 paid registration have reached the Symposium Secretariat.

Please, complete and return this form together with the payment to the Symposium Secretariat:

Doctaforum

Avda. Campo de Calatrava, 17, 4-PB-1, 28034 Madrid - Spain

Tel.: +34 91 372 02 03 - Fax: +34 91 735 04 54 - www.doctaforum.com/aocsymp



Advanced Ovarian Cancer:
OPTIMAL THERAPY. Update

Valencia, Spain, 4th March 2011